FTC Action Requires Firms To Report Research Fairly In Ads

WASHINGTON—A federal agency that polices the accuracy of U.S. advertising has sent a message to industry that it must report scientific results fairly and completely. Last month the Federal Trade Commission (FTC) and the R.J. Reynolds Tobacco Co. reached an agreement on an FTC complaint brought against a 1985 advertisement by Reynolds that discussed the findings from a major National Institutes of Health-funded clinical trial aimed at reducing deaths from coronary heart disease. They

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—A federal agency that polices the accuracy of U.S. advertising has sent a message to industry that it must report scientific results fairly and completely.

Last month the Federal Trade Commission (FTC) and the R.J. Reynolds Tobacco Co. reached an agreement on an FTC complaint brought against a 1985 advertisement by Reynolds that discussed the findings from a major National Institutes of Health-funded clinical trial aimed at reducing deaths from coronary heart disease. They government had accused Reynolds of making false and misleading claims about the results of the study.

Although Reynolds did not concede any errors in its advertisement, it has agreed in the settlement not to misrepresent in future ads the results of this or any other scientific study that involves the relationship between cigarette smoking and health. The settlement also reaffirms the commission’s right to regulate as commercial speech the type of ads that Reynolds ran in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies